Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079295 | 0.83 | MAPK14 (0.44) | SMN1; SMN2LMNANPC1RAB9AMAPK14 | |
| SCHEMBL15007237 | 0.81 | HSD11B1 (0.52) | HSD11B1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL4076128 | 0.81 | MAPK14 (0.44) | HSD11B1PDE2APDE10AKDM4EMAPK14 | |
| SCHEMBL4082120 | 0.80 | PDE2A (0.40) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL4079533 | 0.80 | PTGS1 (0.43) | HSD11B1LMNAMAPK14GAA | |
| SCHEMBL4070456 | 0.79 | MAPK14 (0.37) | ALDH1A1SMN1; SMN2LMNAMAPK14GAA | |
| SCHEMBL4073505 | 0.78 | MAPK14 (0.41) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL4070718 | 0.78 | MAPK14 (0.54) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL4071394 | 0.78 | PDE5A (0.40) | EPHB3MAPK14AHR | |
| SCHEMBL379749 | 0.77 | HSD11B1 (0.48) | HSD11B1ALDH1A1SMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-7321040-B2 | Triazolo-pyridines as anti-inflammatory compounds | PFIZER INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1601672-B1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1601672-A1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050075365-A1 | Novel triazolo-pyridines as anti-inflammatory compounds | PFIZER, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004072072-A1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075365-A1 | Novel triazolo-pyridines as anti-inflammatory compounds | MAPK6, IL6, GRK6 | HSD11B1 3008/4885ALDH1A1 3595/4885SMN1; SMN2 2194/4885 |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | HSD11B1 702/4885ALDH1A1 2400/4885SMN1; SMN2 4055/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | HSD11B1 698/4885ALDH1A1 2388/4885SMN1; SMN2 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.